This protocol is judged by an institutional critique board, an unbiased team that critiques any medical trials involving humans. If a review includes a Program I drug, after the board approves the protocol as ethical, the scientists should apply for an investigational new drug (IND) variety in the FDA.Some scientists and companies contemplate copy